Genetic Technologies Provides U.S. Patent Re-Examination Update

Genetic Technologies Provides U.S. Patent Re-Examination Update 
MELBOURNE, AUSTRALIA -- (Marketwire) -- 03/15/13 --  Genetic
Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce
that the United States Patent and Trademark Office ("USPTO") has now
issued an action reaffirming the validity of certain claims contained
in the Company's U.S. Patent No. 5,612,179 (the '179 patent) directed
to non-coding deoxyribonucleic acid (DNA). 
As announced by the Company on July 9, 2012, Genetic Technologies had
received formal notification from the USPTO that it had received and
granted a request for ex parte re-examination of claims 1-18 and
26-32 of the '179 patent based upon a submission by Merial L.L.C. of
Duluth, Georgia ("Merial"). Merial is currently a defendant in an
action originally brought by the Company in Colorado, USA (as filed
in May 2011 in US District Court, for the District of Colorado) for
infringement of the '179 patent. That action currently is pending in
Delaware Federal District Court. 
In its formal notification to the Company, the USPTO stated that
"claims 1-18 and 26-32 of the '179 patent are confirmed and claims
19-25 and 33-36 are not reexamined". 
"The successful resolution of the re-examination of one of our key
patents will once again reinforce the strength of the Company's
non-coding patent portfolio," said Alison Mew, Chief Executive
Officer of Genetic Technologies. "With the removal of what some
potential licensees have apparently used as a reason to delay
settlement discussions, we hope that such negotiations will now
resume in earnest, with further licenses to our technology then being
granted." 
Safe Harbor Statement
 Any statements in this press release that
relate to the Company's expectations are forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act
The Private Securities Litigation Reform Act of 1995 (PSLRA)
implemented several significant substantive changes affecting certain
cases brought under the federal securities laws, including changes
related to pleading, discovery, liability, class representation and
awards fees and of 1995. Since this information may involve risks and
uncertainties and are subject to change at any time, the Company's
actual results may differ materially from expected results.
Additional risks associated with Genetic Technologies' business can
be found in its periodic filings with the SEC. 
FOR FURTHER INFORMATION PLEASE CONTACT 
Ms. Alison J. Mew
Chief Executive Officer
Genetic Technologies Limited
Phone: +61 3 8412 7000 
Laura Forman (USA)
Blueprint Life Science Group
+1 (415) 375 3340 Ext. 103